Faheem Faheem

Mr. Faheem Faheem

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2020 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
BKBANOTH KARAN KUMAR
BANOTH KARAN KUMAR
FAFaheem
Faheem
KSKondapalli Venkata Gowri Chandra Sekhar
Kondapalli Venkata Gowri Chandra Sekhar
RORupal Ojha
Rupal Ojha
VPVijay kumar Kumar Prajapati
Vijay kumar Kumar Prajapati
MSMurugesan Sankaranarayanan
Murugesan Sankaranarayanan
COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) primarily appeared in Wuhan, China, in December 2019. At present, no proper therapy and vaccinations are available for the disease, and it is increasing day by day with a high mortality rate. Pharmacophore based virtual screening of the selected natural product databases followed by Glide molecular docking and dynamics studies against SARS-CoV-2 main protease was investigated to identify potential ligands that may act as inhibitors. The molecules SN00293542 and SN00382835 revealed the highest docking score of −14.57 and −12.42 kcal/mol, respectively, when compared with the co-crystal ligands of PDB-6Y2F (O6K) and 6W63 (X77) of the SARS-CoV-2 Mpro. To further validate the interactions of top scored molecules SN00293542 and SN00382835, molecular dynamics study of 100 ns was carried out. This indicated that the protein-ligand complex was stable throughout the simulation period, and minimal backbone fluctuations have ensued in the system. Post-MM-GBSA analysis of molecular dynamics data showed free binding energy-71.7004 +/− 7.98, −56.81+/− 7.54 kcal/mol, respectively. The computational study identified several ligands that may act as potential inhibitors of SARS-CoV-2 Mpro. The top-ranked molecules SN00293542, and SN00382835 occupied the active site of the target, the main protease like that of the co-crystal ligand. These molecules may emerge as a promising ligands against SARS-CoV-2 and thus needs further detailed investigations. Communicated by Ramaswamy H. Sarma Graphical Abstract

29 March 2021 in RSC Advances
Verified
Journal Article
Open access
PDF file
FAFaheem
Faheem
BKBANOTH KARAN KUMAR
BANOTH KARAN KUMAR
KSKondapalli Venkata Gowri Chandra Sekhar
Kondapalli Venkata Gowri Chandra Sekhar
SCSubhash Chander
Subhash Chander
SKSelvaraj Kunjiappan
Selvaraj Kunjiappan
MSMurugesan Sankaranarayanan
Murugesan Sankaranarayanan
This review provides critical insights into the biological activities and Structure–Activity Relationship (SAR) studies of tetrahydroisoquinoline (THIQ) analogs.

28 April 2021 in Expert Opinion on Drug Discovery
Verified
Journal Article
Closed access
FAFaheem
Faheem
BKBANOTH KARAN KUMAR
BANOTH KARAN KUMAR
KSKondapalli Venkata Gowri Chandra Sekhar
Kondapalli Venkata Gowri Chandra Sekhar
SCSubhash Chander
Subhash Chander
SKSelvaraj Kunjiappan
Selvaraj Kunjiappan
MSMurugesan Sankaranarayanan
Murugesan Sankaranarayanan
Introduction: Cancer is a dreadful disorder that is emerging as one of the leading causes of mortality across the globe. The complex tumor environment, supplemented with drawbacks of the existing drugs, has made it a global health concern. The Tetrahydroisoquinoline (THIQ) ring holds an important position in medicinal chemistry due to its wide range of pharmacological properties. Several THIQ based natural products have been previously explored for their antitumor properties, making it a vital scaffold for anticancer drug design. Areas covered: This review article addresses the potential of THIQ as anticancer agents. Various medicinal chemistry strategies employed for the design and development of THIQ analogs as inhibitors or modulators of relevant anticancer targets have been discussed in detail. Moreover, the common strategies employed for the synthesis of the core scaffold are also highlighted. Expert opinion: Evidently, THIQs have tremendous potential in anticancer drug design. Some of these analogs exhibited potent activity against various cancer molecular targets. However, there are some drawbacks, such as selectivity that need addressing. The synthetic ease for constructing the core scaffold complimented with its reactivity makes it ideal for further structure-activity relationship studies. For these reasons, THIQ is a privileged scaffold for the design and development of novel anticancer agents.

31 October 2022 in Viruses
Verified
Journal Article
Open access
PDF file
AMAlexander McAuley
Alexander McAuley
PVPetrus Jansen Van Vuren
Petrus Jansen Van Vuren
MRMuzaffar Ur Rehman
Muzaffar Ur Rehman
FAFaheem
Faheem
SGSarah Goldie
Sarah Goldie
SVSeshadri S Vasan
Seshadri S Vasan
The repurposing of licenced drugs for use against COVID-19 is one of the most rapid ways to develop new and alternative therapeutic options to manage the ongoing pandemic. Given circa 7817 licenced compounds available from Compounds Australia that can be screened, this paper demonstrates the utility of commercially available ex vivo/3D airway and alveolar tissue models. These models are a closer representation of in vivo studies than in vitro models, but retain the benefits of rapid in vitro screening for drug efficacy. We demonstrate that several existing drugs appear to show anti-SARS-CoV-2 activity against both SARS-CoV-2 Delta and Omicron Variants of Concern in the airway model. In particular, fluvoxamine, as well as aprepitant, everolimus, and sirolimus, has virus reduction efficacy comparable to the current standard of care (remdesivir, molnupiravir, nirmatrelvir). Whilst these results are encouraging, further testing and efficacy studies are required before clinical use can be considered.

6 September 2021 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
BKBANOTH KARAN KUMAR
BANOTH KARAN KUMAR
FAFaheem
Faheem
RFRafael Balana Fouce
Rafael Balana Fouce
EMEstela Melcon-Fernandez
Estela Melcon-Fernandez
YYYolanda Perez-Pertejo Yolanda
Yolanda Perez-Pertejo Yolanda
MSMurugesan Sankaranarayanan
Murugesan Sankaranarayanan
Leishmaniasis is one of today's most neglected diseases. The emergence of new anti-leishmanial therapies emphasizes several study groups funded by the World Health Organization. The present investigation will focus on the research to determine a few new potential derivatives of β-carboline ester derivatives against leishmaniasis. The in-silico predicted ADMET properties of most of the titled compounds are in an acceptable range and having drug like properties. Among all the tested analogs, compound ES-3 (EC50 3.36 μM; SI > 29.80) showed comparable and equipotent anti-leishmanial activity as that of standard drug miltefosine (EC50 4.80 μM; SI > 20.80) against amastigote forms of the tested L. infantum strain. Two compounds ES-6 and ES-10 exhibited significant activity with EC50 10.16, 13.56 μM; SI > 4.90, 7.37, respectively. In-silico based molecular docking and dynamics study of the significantly active analog also performed to study the putative binding mode, interaction pattern at the active site of the target leishmanial trypanothione reductase enzyme as well as stability of the target-ligand complex. The changes in the conformation of molecules during MD (frame wise trajectory analysis) provided new insights for the development of novel potent molecules. These findings will further give insight that will help modify the compound ES-3 for better potency and the design of novel inhibitors for leishmaniasis. Communicated by Ramaswamy H. Sarma Graphical Abstract

Verified
Journal Article
Open access
PDF file
CMChris Macraild
Chris Macraild
MRMuzaffar Ur Rehman
Muzaffar Ur Rehman
FAFaheem
Faheem
MSMurugesan Sankaranarayanan
Murugesan Sankaranarayanan
ISIan K. Styles
Ian K. Styles
SVSeshadri S Vasan
Seshadri S Vasan
SARS-CoV-2 is the cause of the COVID-19 pandemic which has claimed more than 6.5 million lives worldwide, devastating the economy and overwhelming healthcare systems globally. The development of new drug molecules and vaccines has played a critical role in managing the pandemic; however, new variants of concern still pose a significant threat as the current vaccines cannot prevent all infections. This situation calls for the collaboration of biomedical scientists and healthcare workers across the world. Repurposing approved drugs is an effective way of fast-tracking new treatments for recently emerged diseases. To this end, we have assembled and curated a database consisting of 7817 compounds from the Compounds Australia Open Drug collection. We developed a set of eight filters based on indicators of efficacy and safety that were applied sequentially to down-select drugs that showed promise for drug repurposing efforts against SARS-CoV-2. Considerable effort was made to evaluate approximately 14,000 assay data points for SARS-CoV-2 FDA/TGA-approved drugs and provide an average activity score for 3539 compounds. The filtering process identified 12 FDA-approved molecules with established safety profiles that have plausible mechanisms for treating COVID-19 disease. The methodology developed in our study provides a template for prioritising drug candidates that can be repurposed for the safe, efficacious, and cost-effective treatment of COVID-19, long COVID, or any other future disease. We present our database in an easy-to-use interactive interface (CoviRx that was also developed to enable the scientific community to access to the data of over 7000 potential drugs and to implement alternative prioritisation and down-selection strategies.